유방암 환자에서 체질량지수에 따른 선행항암화학요법의 효과
Body Mass Index and Response to Neoadjuvant Chemotherapy in Korean Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The relationship between neoadjuvant chemotherapy (NAC) and body mass index (BMI) in breast cancer patients has been reported in many studies. Which have suggested that obesity is associated with a poor prognosis in breast cancer patients in Western countries, but not in breast cancer patients from Asian countries. We studied the relationship between response to chemotherapy, survival and BMI. Methods: A total of 217 Korean breast cancer patients were enrolled in the study, and 170 underwent magnetic resonance imaging scan prior to chemotherapy. The BMI of the patients was calculated using their age, weight, and height. The following factors were analyzed: chemotherapy regimen, tumor size before and after NAC, surgical procedure, pathological tumor size, lymph node status, nuclear grade, histological grade, hormone receptor status, and epidermal growth factor receptor expression. Disease-free survival (DFS) and overall survival (OS) were determined using recent medical records. According to the World Health Organization’s classification of BMI, patients were divided into four groups: ≤18.5, underweight; 18.5 to 24.9, normal weight; 25 to 29.9, overweight; ≥30, obesity. The underweight and normal weight patients were combined to from group A, whereas the overweight and obese patients were combined to from group B. DFS and OS were calculated using the Kaplan-Meier method. Results: In this study, there were 113 patients (66.5%) in group A, and 57 patients (33.5%) in group B. When the two groups were compared, age was the only factor that showed a statistically significant difference. Clinical complete remission (p=0.98), pathological complete remission (p=0.63), OS (p=0.64), and DFS (p=0.10) did not correlate with BMI. Conclusion: Treatment response and survival were not associated with BMI in Korean breast cancer patients who received NAC.
Abstract
Purpose: The relationship between neoadjuvant chemotherapy (NAC) and body mass index (BMI) in breast cancer patients has been reported in many studies. Which have suggested that obesity is associated with a poor prognosis in breast cancer patients in Western countries, but not in breast cancer patients from Asian countries. We studied the relationship between response to chemotherapy, survival and BMI. Methods: A total of 217 Korean breast cancer patients were enrolled in the study, and 170 underwent magnetic resonance imaging scan prior to chemotherapy. The BMI of the patients was calculated using their age, weight, and height. The following factors were analyzed: chemotherapy regimen, tumor size before and after NAC, surgical procedure, pathological tumor size, lymph node status, nuclear grade, histological grade, hormone receptor status, and epidermal growth factor receptor expression. Disease-free survival (DFS) and overall survival (OS) were determined using recent medical records. According to the World Health Organization’s classification of BMI, patients were divided into four groups: ≤18.5, underweight; 18.5 to 24.9, normal weight; 25 to 29.9, overweight; ≥30, obesity. The underweight and normal weight patients were combined to from group A, whereas the overweight and obese patients were combined to from group B. DFS and OS were calculated using the Kaplan-Meier method. Results: In this study, there were 113 patients (66.5%) in group A, and 57 patients (33.5%) in group B. When the two groups were compared, age was the only factor that showed a statistically significant difference. Clinical complete remission (p=0.98), pathological complete remission (p=0.63), OS (p=0.64), and DFS (p=0.10) did not correlate with BMI. Conclusion: Treatment response and survival were not associated with BMI in Korean breast cancer patients who received NAC.
참고문헌 (27)
- Jemal A, "Global cancer statistics", CA Cancer J Clin, 61, pp.69~90 (2011)
- Annual Report of Cancer Statistics in Korea in 2009, "The Korea Central Cancer Registry", The Korea Central Cancer Registry, ~ (2011)
- Cianfrocca M, "Prognostic and predictive factors in early-stage breast cancer", Oncologist, 9, pp.606~616 (2004)
- Slamon DJ, "Human breast cancer : correlation of relapse and survival with amplification of the HER-2", neu oncogene, 1987, pp.235, 177~182
- van den Brandt PA, "Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk", Am J Epidemiol, 152, pp.514~527 (2000)
- Morimoto LM, "Obesity, body size, and risk of postmenopausal breast cancer: the Women’s Health Initiative (United States)", Cancer Causes Control, 13, pp.741~751 (2002)
- WHO Expert Consultation, "Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies", Lancet, 363, pp.157~163 (2004)
- Bastarrachea J, "Obesity as an adverse prognostic factor for patients receiving adjuvant chemotherapy for breast cancer", Ann Intern Med, 120, pp.18~25 (1994)
- Carmichael AR, "Obesity as a risk factor for development and poor prognosis of breast cancer", BJOG, 113, pp.1160~1166 (2006)
- Goodwin PJ, "Fasting insulin and outcome in early-stage breast cancer : results of a prospective cohort study", J Clin Oncol, 20, pp.42~51 (2002)
- McTiernan A, "Adiposity and sex hormones in postmenopausal breast cancer survivors", J Clin Oncol, 21, pp.1961~1966 (2003)
- Cui Y, "Body mass and stage of breast cancer at diagnosis", Int J Cancer, 98, pp.279~283 (2002)
- Zumoff B, "Relationship between body weight and the incidence of positive axillary nodes at mastectomy for breast cancer", J Surg Oncol, 22, pp.217~220 (1983)
- Dignam JJ, "Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer", Breast Cancer Res Treat, 97, pp.245~254 (2006)
- Chen S, "Obesity or overweight is associated with worse pathological response to neoadjuvant chemotherapy among Chinese women with breast cancer", PLoS One, 7, pp.e41380~ (2012)
- Kyung Hun Lee, "Body Mass Index Is Not Associated with Treatment Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy: Korean Data", Journal of Breast Cancer, 15(4), pp.427~433 (2012), 한국유방암학회[DOI]
- Eisenhauer EA, "New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)", Eur J Cancer, 45, pp.228~247 (2009)
- The Korean Breast Cancer Society, "The Breast", pp.128~129 (1999), Ilchokak
- Bae MK, "The factors associated with body mass index of adults", J Korean Acad Fam Med, 20, pp.906~916 (1999)
- Health implications of obesity, "National Institutes of Health Consensus Development Conference Statement", Ann Intern Med, 103(6 Pt 2), pp.1073~1077 (1985)
- Newman SC, "The effect of body mass index and oestrogen receptor level on survival of breast cancer patients", Int J Epidemiol, 26, pp.484~490 (1997)
- Männistö S, "Body-size indicators and risk of breast cancer according to menopause and estrogen-receptor status", Int J Cancer, 68, pp.8~13 (1996)
- Ruder AM, "Estrogen and progesterone receptors in breast cancer patients : epidemiologic characteristics and survival differences", Cancer, 64, pp.196~202 (1989)
- Giuffrida D, "Relation between steroid receptor status and body weight in breast cancer patients", Eur J Cancer, 28, pp.112~115 (1992)
- Howson CP, "weight, serum cholesterol, and stage of primary breast cancer", Cancer, 58, pp.2372~2381 (1986)
- Keun-YoungYoo, "Epidemiology of Breast Cancer in Korea: Occurrence, High-Risk Groups, and Prevention", Journal of Korean Medical Science, 17(1), pp.1~6 (2002), 대한의학회
- Moon HG, "Underweight and breast cancer recurrence and death : a report from the Korean Breast Cancer Society", J Clin Oncol, 27, pp.5899~5905 (2009)